NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.

Core Insights - NeuroPace, Inc. has completed the repurchase of 5,270,845 shares from KCK Ltd., allowing KCK to sell all remaining shares it held in the company [1] - The repurchase was funded using proceeds from a recent underwritten public offering, which has strengthened NeuroPace's balance sheet and is expected to support operations until cash flow breakeven is achieved [1][2] - The company has terminated its current at-the-market offering program following the completion of the public offering [1] Financial Position - The recent financing has provided sufficient cash runway for NeuroPace to execute its long-range plan and achieve cash flow breakeven [2] - The company expressed gratitude to KCK Ltd. for its support over the years [2] Product and Market Focus - NeuroPace is dedicated to transforming the lives of individuals with epilepsy through its RNS System, which is the first commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - The RNS System aims to improve care standards for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3]